Ginkgo Results Presentation Deck

Biotechnology products take significant time to get to market; both scale and diversity are needed to achieve predictable cash flows Downstream "Present Value" Will Move with Broader Markets Equity: Drop in growth & biotech valuations drives lower marks for existing equity positions Effect is felt immediately as equity is a present value measurement (of expected future value) Cash Milestones & Royalties: Milestones and royalties are only paid upon program success / commercialization and are thus delayed Higher discount rates similarly drive a lower NPV for these future expected payments Ended 2021 with over $1.5 billion in cash Provides meaningful multi-year runway as we drive towards profitability Risk Tunable Balance of Risk Sharing We can adjust the balance between upfront fees and downstream value based on the customer and Ginkgo's position No / Low Upfront Fees High Downstream Value High Upfront Fees No / Low Downstream Value (e.g. a traditional CRO model) When profitable / well capitalized, can lean into our differentiated p(success) Can shift focus towards need to preserve cash cost-covering upfront fees if Return if successful 25 Property of Ginkgo Bioworks 2021 UPDATE & BUSINESS REVIEW

View entire presentation